Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | completed | Phase 2 | 78 | Cancer Research UKOTHER | 1 | May 24, 2016 | clinicaltrials |
| NCT00002558 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | completed | Phase 1 / Phase 2 | 108 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2016 |
| clinicaltrials |
| NCT00423852 | Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | completed | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00985738 | Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer | terminated | Phase 2 | 16 | University of Colorado, DenverOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00321646 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 42 | Mary-Ellen Taplin, MDOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT00459186 | The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT02423889 | Stereotactic Volumetric Radiotherapy in Prostate Cancer | completed | Phase 2 | 28 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00121238 | Cilengitide in Treating Patients With Prostate Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT02484339 | Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)(α-RT) | unknown | Phase 2 | 274 | University Hospital FreiburgOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00634894 | Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00707356 | Study of WST11 in Patients With Localized Prostate Cancer | completed | Phase 2 | 42 | Steba Biotech S.A.OTHER | 3 | Apr 19, 2016 | clinicaltrials |
| NCT00345293 | Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer | completed | Phase 1 / Phase 2 | 13 | Rockefeller UniversityOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01812746 | A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | BIND TherapeuticsINDUSTRY | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck(iNSITE2) | terminated | Phase 2 | 73 | BIND TherapeuticsINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT02324595 | Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study(MISSION) | completed | Phase 2 | 30 | Catholic University of the Sacred HeartOTHER | 1 | Apr 13, 2016 | clinicaltrials |
| NCT00064025 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | completed | Phase 2 | 75 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2016 | clinicaltrials |
| NCT01046916 | Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen | completed | Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00170664 | Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 129 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00203424 | Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib | completed | Phase 2 | 23 | Translational Oncology Research InternationalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00583492 | Randomized Trial of Suicide Gene Therapy and Prostate Cancer(ReCAP) | completed | Phase 2 | 44 | Henry Ford Health SystemOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033123 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | completed | Phase 2 | 41 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01033292 | A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 43 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01603420 | External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | terminated | Phase 2 / Phase 3 | 2 | Proton Collaborative GroupNETWORK | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00003334 | Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT02341404 | A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer | completed | Phase 2 | 23 | Lidds ABINDUSTRY | 2 | Mar 11, 2016 | clinicaltrials |
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02705612 | Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer | unknown | Phase 2 | 60 | Air Force Military Medical University, ChinaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00438464 | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery | completed | Phase 2 | 204 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00526799 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 30 | Daniela Matei, MDOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00522301 | Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT02490748 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer | active not recruiting | Phase 2 | 10 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | completed | Phase 2 | 23 | Daniela Matei, MDOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02035124 | Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00284427 | Safety of Antioxidants During GYN Cancer Care | completed | Phase 2 | 25 | Jeanne Drisko, MD, CNS, FACNOTHER | 0 | Feb 10, 2016 | clinicaltrials |
| NCT00454571 | Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer(PITCH) | completed | Phase 1 / Phase 2 | 21 | Leiden University Medical CenterOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00085566 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 20, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00588237 | Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00124566 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | completed | Phase 2 | 135 | Eisai Inc.INDUSTRY | 9 | Jan 18, 2016 | clinicaltrials |
| NCT00401674 | MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer(MITO-5) | completed | Phase 2 | 26 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2016source: clinicaltrials